BNR has been the subject of a number of other research reports. Citigroup set a €60.00 ($71.43) target price on shares of Brenntag and gave the stock a buy rating in a research report on Thursday, October 19th. Commerzbank set a €57.00 ($67.86) target price on shares of Brenntag and gave the stock a neutral rating in a research report on Tuesday, November 14th. UBS Group set a €53.00 ($63.10) price objective on shares of Brenntag and gave the stock a neutral rating in a report on Monday, January 8th. Jefferies Group set a €60.00 ($71.43) price objective on shares of Brenntag and gave the stock a buy rating in a report on Tuesday, November 14th. Finally, Goldman Sachs Group set a €56.00 ($66.67) price objective on shares of Brenntag and gave the stock a neutral rating in a report on Tuesday, December 19th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of €56.50 ($67.26).
Brenntag (FRA:BNR) opened at €53.08 ($63.19) on Wednesday. The firm has a market cap of $8,450.00 and a price-to-earnings ratio of 20.49. Brenntag has a 52-week low of €43.06 ($51.26) and a 52-week high of €56.25 ($66.96).
COPYRIGHT VIOLATION WARNING: This news story was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2018/01/13/hsbc-reiterates-60-00-price-target-for-brenntag-bnr.html.
Brenntag Company Profile
Brenntag AG, a chemical distribution company, provides distribution solutions for industrial and specialty chemicals worldwide. The company also provides value added services. It serves customers in various end-market industries, such as adhesives, paints, oil and gas, food, water treatment, personal care, and pharmaceuticals.
Receive News & Ratings for Brenntag Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brenntag and related companies with MarketBeat.com's FREE daily email newsletter.